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Abstract
Introduction: Diabetes is a worldwide high prevalence chronic progressive disease that poses a significant challenge to
healthcare systems. The aim of this study is to provide a detailed economic burden of diagnosed type 2 diabetes mellitus
(T2DM) and its complications in Iran in 2009 year.
Methods: This is a prevalence-based cost-of-illness study focusing on quantifying direct health care costs by bottom-up
approach. Data on inpatient hospital services, outpatient clinic visits, physician services, drugs, laboratory test, education
and non-medical cost were collected from two national registries. The human capital approach was used to calculate
indirect costs separately in male and female and also among different age groups.
Results: The total national cost of diagnosed T2DM in 2009 is estimated at 3.78 billion USA dollars (USD) including
2.0460.28 billion direct (medical and non-medical) costs and indirect costs of 1.73 million. Average direct and indirect cost
per capita was 842.66102 and 864.8 USD respectively. Complications (48.9%) and drugs (23.8%) were main components of
direct cost. The largest components of medical expenditures attributed to diabetes’s complications are cardiovascular
disease (42.3% of total Complications cost), nephropathy (23%) and ophthalmic complications (14%). Indirect costs include
temporarily disability (335.7 million), permanent disability (452.4 million) and reduced productivity due to premature
mortality (950.3 million).
Conclusions: T2DM is a costly disease in the Iran healthcare system and consume more than 8.69% of total health
expenditure. In addition to these quantified costs, T2DM imposes high intangible costs on society in terms of reduced
quality of life. Identification of effective new strategies for the control of diabetes and its complications is a public health
priority.
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Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease
characterized by hyperglycemia and dyslipidemia due to under-
lying insulin resistance. The condition commonly progresses to
include microvascular [e.g., retinopathy, nephropathy, and
neuropathy] and macrovascular [e.g., heart, cerebral, and
peripheral vascular disease] complications [1,2].
The risk of diabetes continues to increase worldwide and its
public health burden is unevenly distributed across socioeconomic
strata [3,4]. This burden is not only related to health care costs,
but also to indirect costs caused by loss of productivity from
disability and premature mortality [5]. The most recent data from
the International Diabetes Federation (IDF) indicate that diabetes
currently affects 246 million people worldwide and is expected to
affect 380 million by 2025 [6]. The Middle East is expected to
bear one of the world’s greatest increases in the absolute burden of
diabetes in the coming decades [7].
According to IDF estimations global health expenditures to
prevent and treat diabetes and its complications was at least 376
billion US dollar (USD) in 2010. By 2030, this number will exceed
490 billion USD. There is a large disparity in healthcare spending
on diabetes between regions and countries. More than 80% of the
global expenditures on diabetes are made in the world’s
economically richest countries, not in the low- and middle-income
countries where 80% of people with diabetes will soon live [6].
However, the ultimate goal of prevention of T2DM is to
improve the prognosis and overall quality of life of affected
individuals, and with regard to health policy, also to prevent
increasing costs of the treatment of T2DM and its complications
[8]. Knowledge of the costs of diabetes improves understanding of
the importance of addressing health care and prevention issues
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for researchers intending to evaluate alternative interventions for
the management of diabetes is scarcity of cost data especially on
T2DM [9]. Since there are few studies regarding cost of diabetes
in Iran and Middle East countries, particularly about T2DM and
its complications, therefore the aim of this study is to give a better
economic perspective of cost of T2DM in Iran for health policy
making.
Methods
Study design
This is a prevalence-based cost of illness (COI) study focusing on
direct health care costs. A multipoint data collection procedure
based on the patient medical records beside diabetes prevalence
rates and other epidemiological data, health care costs, and
economic data used in order to obtain the necessary data for the
analysis and the construction of Cost of T2DM Model. The
perspective for this study was society of Iran. As well as direct
costs, the analysis incorporated indirect costs. These costs included
loss of productivity due to temporarily and permanent disability
and labor loss due to premature mortality [10].
Study Subjects and Sampling Design
As a part of a national survey of diabetes prevention and control
programme, using a multistage cluster randomized sampling
method, 4500 subjects were recruited from Tehran and Fars
province, capital and south of Iran respectively with a population
of around 18.5 million (about 25.5% of the Iranian total
population). Each province as strata of study sample has seven
clusters for urban and rural regions, which were selected
randomly. To produce the target sample size, subjects were
selected using the probabilities proportional to their region
population. Subjects were eligible for the study if at the first they
met WHO criteria (fasting plasma glucose $7.0 mmol/l (126 mg/
dl) or with a glucose tolerance test, two hours after the oral dose a
plasma glucose $11.1 mmol/l (200 mg/dl)). Second at least they
received routine care of diabetic patients included: regular visits
for glycemic control and screening for complications, regular
laboratory investigations and medications for one year. Third were
age 18 years or older and forth were willing and able to give
written informed consent and complete the questionnaire
interview that composed of the following sections: Section A-
demography and background information, Section B- diabetic
care, Section C- outpatient care, Section D- inpatient care and
Section E- informal care and other direct non medical cost and
indirect cost. General Characteristics of Subjects showed in table 1.
Determining direct medical costs
The approach used to estimate medical costs largely follow the
investigating medical records of people with diagnosed T2DM -
were registered in several participating centers- by bottom-up
approach. All patients attended diabetes clinics every 2 or 3
months for the duration of the study. At each visit they were
precisely assessed to determine the occurrence of any clinical
events or hospital episodes since the previous visit. Full clinical and
cost information on hospital in-patient stays was collated by each
clinic based on patient interviews at every clinic visit. Information
on non-in-patient health care resources was obtained using a
questionnaire (section c) distributed at clinic visits during the
survey period. This survey recorded information on all contacts
with general practitioners, nurses, podiatrists, opticians, and
dieticians, other hospital out-patient clinics and any other
pharmaceutical, diagnostic and rehabilitative care received during
the survey. The total costs over this period were estimated by
multiplying the number of each care by unit costs for each type of
care and the resulting total cost was then annualized. To
investigate the distribution of costs across each cost component,
resource utilization was separated in to six categories: costs of visits
to specialists; pharmaceutical and device, laboratory/diagnostic
tests, inpatient and educational cost for patients without
complication and costs associated with complications. All health
care resources utilization categorized for patients with and without
complication. The estimated aggregate total annual direct medical
costs associated with T2DM and its complications were calculated
for the population of Iran on the basis of age and sex-specific
prevalence rates of T2DM and its complications (table 2).
Determining direct nonmedical costs
Non-medical expenditures include costs for services such as
transportation for the patient and family members to clinics that
estimated from the patient’s self-estimate questionnaire and costs
for taking care of dependents (informal care that not included as
part of direct health care costs). The cost of T2DM related
informal care was estimated using Posnett and Jan’s method for
measuring the opportunity cost of unpaid inputs [17]. The average
net hourly wage was applied to informal care provided by carers
under 65 year who were economically active and in employment
[18].
Determining costs of lost productivity
In this study the total indirect costs associated with T2DM
categorized in three groups. Health-related days absent from work
and reduced job performance due to health problems (Tempo-
rarily Disability), reduced earnings capacity from permanent
disabilities, and lost productivity from premature mortality. we
asked patients number of days in year who couldn’t be in their job
due to seeking diabetes related health care or rested in home to get
better (temporarily disability) in E section of questionnaire. Then
we used their insurance ID to retrieve their indemnity claims
during one year from social security organization (SSO) database.
It should be noted that SSO data would lead to an underestimate
of the number of disabled people because it provides data on the
number of people who receive disability benefits. The number of
people who are actually disabled exceeds the number who receives
benefits. So we made some adjustments according to respondents’
declarations. Also according to each patient’s condition and their
complication’s disability weight -obtained from SSO data on
disability by condition- [19] we calculated annual permanently
disability costs. Mortality costs are calculated as the lost earnings
due to premature mortality. The number of years of life lost,
estimated by using Iran’s life table (2009) and number of death in
different age and sex group attributable to T2DM. The
productivity loss for people employed in the workforce is
calculated by combining age-sex–specific estimates of workforce
participation rates (estimated from the Statistics Center of Iran
(SCI)), average earnings (from the Central Bank of the Iran (CBI)),
and the size of the population with diagnosed T2DM. The
earnings in future years are discounted (3% discount rate, a rate
often used in public health studies) and one percent real annual
growth rate in earnings is assumed. We assume that the value of
productivity generated for the population age 20–69 who is not
employed is 75% of the value of employed people of the same age
and sex [10,17]. Also we assumed that productivity loss cost for
population age 70 and older is zero. To have an international
perspective both direct and indirect costs were converted from
Iranian Rials [IRR], into USD at an official currency exchange
rate of 9,920 IRR/1 USD 2009 [20].
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Healthcare cost data often have several characteristics that must
be addressed through the careful selection of appropriate statistical
analyses [9]. Within a defined period (e.g.1 year) significant
proportions of individuals have no contact with some types of
healthcare providers and so incur no costs. However, amongst the
individuals who do make use of health services, the cost data are
typically right-skewed because a relatively small proportion of
patients incur extremely high costs. Even if the estimate is
unbiased from the linear regression models, it could be unstable
given the skewness and kurtosis of the data distribution, and
inefficient due to the heteroskedasticity [21]. Such problems were
dealt with by logarithmic or other transformation of the cost data.
We used the generalized linear model (GLM) with log-link and
gamma variance functions which assume patient characteristics
and complications have a multiplicative effect on costs to identify
the relationship between complications and costs after controlling
for covariates (including; sex, age and location (urban or rural)).
Also we used standardized sampling weights for data analyzing.
Attheend because arange ofsources and assumptionswereused,
thereis inevitably some uncertainty intheestimatedcosts ofT2DM.
Therefore sensitivity analysis was conducted on direct and indirect
costs to test the robustness of the assumption and to examine the
impact of potential outliers in the claim database. The effects of
20% changes in the baseline resource quantities, unit costs, and
other key data on direct health care costs and productivity loss were
tested. The effects of changes in discount rates on productivity cost
were assessed by using rates of 3% and 5%.
Results
Total numbers of Iranian people with diagnosed T2DM has
been estimated approximately 2.43 million in 2009. The total
Table 1. General Characteristics of Subjects.
Characteristic category Subcategory Number (%)
Province Tehran 3424 (76)
Fars 1076 (24)
Region Urban 3561 (79)
Rural 939 (21)
Sex Male 1980 (44)
Female 2520 (56)
Age 20–29 54 (1.2)
30–39 463 (10.3)
40–49 1116 (24.8)
50–59 1611 (35.8)
60–69 896 (19.9)
.70 360 (8)
Insurance Social Insured 4212 (94)
Private insured 83 (1.4)
Uninsured 205 (4.6)
Employment status Employed 1591 (35.4)
Student, housewives, voluntary workforce 2480 (55.1)
unemployed 428 (9.5)
Education University education 1028 (22.8)
Non entrance university 950 (21.1)
Illiterate 2522 (56)
doi:10.1371/journal.pone.0026864.t001
Table 2. Diabetes-related complications included in the regression analysis, with diagnostic definitions and theirs prevalence in
Iran.
Complication ICD-9 Prevalence Reference
Cardiovascular disease 401–405, 410, 411, 412, 413, 414–414.8 28% [11]
Neuropathy 250.6 41.60% [12]
Peripheral vascular disease 440, 443, 451,452,454, 459.8–459.9, 14.30% [13]
Nephropathy 580–586 25.60% [14]
Ophthalmic complications 362.01–362.07, 366, 365 37.00% [15]
Diabetic foot 736, 707 4% [16]
doi:10.1371/journal.pone.0026864.t002
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[USD]. It consists of direct medical and non-medical costs
2.0460.28 billion and indirect cost of 1.73 billion. Average
medical cost per capita was 842.66102 USD. The largest
components of per capita medical expenditures are complications
cost 412.8664.5 USD (48.9%); drugs 200.6633 (23.8%), inpatient
services 80612.7 (9.5%) and Laboratory tests 76611 (9%). About
8.69 percent of total health care expenditure in Iran is attributable
to diagnosed T2DM (Table 3).
The cost of complications attributable to diagnosed T2DM
accounted for a 1.00260.14 billion USD in Iran’s health system
cost (more than 4.25% of Iran’s total health expenditure). Per
capita direct cost in patients with one or more complications was 2
times higher than those without complications. Cardiovascular
disease 424.8687 million USD, nephropathy 229649 and
ophthalmic complications 140621.5 are main component of
complication cost in both sexes with 42.3%, 23% and 14%
respectively. Table 4 shows medical cost of each complication in
both sexes separately. Estimated per capita cost of managing
neuropathy and nephropathy complications in males are higher
than females and this difference was statistically significant (P-
value,0.05) however total complications per capita cost was not
different.
The national cost of lost productivity associated with diabetes is
estimated at 1.73 billion USD. This includes temporarily disability
(335.7 million), permanent disability (452.4 million) and reduced
productivity due to premature mortality (950.3 million). Average
per capita indirect cost was 864.8 USD that equal 19 percent of
Iranian per capita national income. Based on Iran’s SSO data we
have concluded that average lost number of workdays per
employed person per year is 17.7 included health related
absenteeism and productivity loss while at work (Temporarily
Disability). As well as these patients lost 23.8 work days due to
permanent disability annually. Also according to estimated
number of deaths in males and females attributable to T2DM in
the 20–69 age-group in Iran by IDF , we calculated total number
of work days lost due to premature mortality 152 million days.
Temporarily and permanent disability and premature mortality
account for 19.3%, 26% and 54.7% of total indirect cost
respectively. As showed in table 5 the population with the highest
productivity loss due to temporarily and permanent disability and
premature mortality are in 40–59, 40–59 and 60–69 age groups
respectively.
In the one way sensitivity analysis, 20% change in assumptions
concerning to health care utilization and unit costs of health care
used in each complication was not most sensitive to assumptions -
resulted in only moderate changes in direct health care cost (15–
19% change). We have concluded that present value of future
productivity loss due to premature mortality is sensitive to the
chosen discount rate, each percentage point increase in the
discount rate causing the Iran total productivity loss drop by 5.3
percent (about 92 million).
Discussion
A synthesis of the published literature showing that one of the
world’s greatest increases in the absolute burden of diabetes in the
coming decades will be happen in Middle East [6,22]. Most of this
increase is anticipated to affect the economically productive 45–64
year old age segment in contrast with most developed countries,
where the increase in patients with diabetes will occur in those
aged $65 years [23].
There is a wide variety of COI on diabetes in developed
countries. However, these estimates vary substantially based on
what has been left out and what has been included as costs. In
addition, it seems almost difficult to compare costs between
countries as these costs often represent decisions which are made
in each country regarding health care financing and delivery [24]
but in order to evaluate the magnitude of the economic burden of
diabetes, it is useful to compare the cost estimates of T2DM in
Iran with other countries. The results of our analysis indicate that
T2DM is a costly disease for Iran’s health care system. We
estimated total direct cost attributable to T2DM approximately
2.04 billion [USD]. Our study showed that the main component of
direct cost in patients without complication was drug (46%) which
is in agreement with Esteghamati and his colleague’s study [25]
that estimated medications and device as a main component of
direct cost with 33 percent proportion.
We found that average annual direct cost per patient was 842.6
[USD], while respective findings of published studies performed in
United State in 2008 -that concluded, diabetes is responsible for
6,649 dollar in excess expenditures per year per person- [10]
revealed that annual per capita direct cost in Iran is about one
third of USA one’s, - based on purchasing power parities (PPP),
which is a method of measuring the relative purchasing power of
the currencies of different countries over the same types of goods
and services, by eliminating the differences in price levels between
countries. Also Estimated average per capita costs of diabetes
mellitus in Latin America and the Caribbean were USD 703;
highest in Cuba (USD 1219) and lowest in Colombia (USD 442) in
2000 [5]. Similarly a recent study assessing the treatment costs of
diabetics in Karachi – Pakistan [26] estimated the annual mean
treatment costs per DM patient to be 197. Given that in Iran more
Table 3. Per capita and total direct cost attributable to T2DM [USD].
Resource category Per capita (USD) % of Total direct cost Iran(million USD)
% of Iran’s Total Health
Expenditure
Physician visit 50.965.6 6 123.7611.5 0.52
Drug prescription 200.6633 23.8 487.8644.1 2.07
Laboratory use 76611 9 184628 0.78
Education 4.260.8 0.5 10.262.7 0.04
Inpatient 80612.7 9.5 194.5632.3 0.83
Complications 412.4664.5 48.9 1002.76140 4.25
Non medical 18.563.2 2.2 4569.8 0.19
Total direct cost 842.66102 100 2048.86280.6 8.69
doi:10.1371/journal.pone.0026864.t003
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expenditure; this represents a significant burden for the individual
with T2DM.
We found that annual per capita cost of T2DM patients was 3.1
times higher than average per capita health care expenditure in
Iran (842.6 vs. 269 USD in 2009). While Esteghamti and his
colleague estimated that annual per capita direct cost of T2DM
were 2.9 time higher than those non diabetic participants in their
study [25]. Meanwhile in USA people with diabetes have health
care expenditures that are 2.3 times higher than expenditures for
this same population would be in the absence of diabetes [10].
According to our result 48.9% of total T2DM direct medical cost
is attributable to its complications; in accordance with result of
other studies that conducted in Iran and USA [25,10] and
estimated this number 53% and 50% respectively. We concluded
that per capita direct cost in patients with one or more
complications was about 2 times higher than those without
complications, while respective finding in Iran and UAE were 1.88
and 9.4 respectively [25,27]. We found that cardiovascular disease
was main component (42.3%) of complication cost. Jaime Caro
and his colleagues estimated that management of macrovascular
disease is estimated to be the largest cost component, accounting
for 52% of the complication costs [28]. Estimated per capita cost
of managing neurological and nephropathy complications in males
was higher than females, but total per capita cost in both sexes is
not significantly different (table 4). This finding should be
interpreted discreetly, since we estimated spending on each
complication for male and female in average and difference in
expenditure can be due to other reasons such as high prevalence
and severity of neuropathy and nephropathy complications in
male compared to female.
Costs of Diagnosed T2DM, accounts for about 8.96 percent of
Iran’s total health expenditure in 2009 (without taking into
account other type of diabetes and undiagnosed patients) while a
study conducted in Iran in 2005 [25] showed that this proportion
was 5.5%. Since health care utilization patterns and economic
Table 4. Health care expenditures attributed to T2DM complications [USD].
Per capita cost USD [95% CI] Total cost million USD [95% CI]
Medical condition Male Female Male Female Both sex
% of Total
Complication Cost
Cardiovascular disease 158.5 [134.1–182.8] 186.1 [148.2–224.8] 162.9 [128–196.3] 261.2 [208.6– 314.3] 424.8 [336.6–510.1] 42.3
Neuropathy 13.7 [11.7–15.8] 3.5 [2.9–4.1] 14 [11.6–16.4] 4.9 [3.8–6] 18.9 [15.4–22.4] 1.9
Peripheral vascular disease 31.3 [26.4–36.4] 35.6 [29.8–41.5] 32.1 [27.8–36.4] 49.9 [40.2–59.6] 82.1 [68–96] 8.2
Nephropathy 134.8 [108 – 160.5] 64.5 [48.2 – 80.3] 138.2 [103–173.3] 90.5 [76.6–104.5] 229 [179.6–274.8] 23
Ophthalmic complications 54.7 [42.3 – 66.5] 59.7 [47.1 – 72.1] 56.2 [47.1–65.3] 83.8 [71.4–96.2] 140 [118.5–161.5] 14
Diabetic foot 36.8 [32.2 – 41.3] 49.4 [41.2 – 57.1] 37.8 [31.2–44.4] 69.3 [59.6–78] 107.1 [90.8–122.4] 10.7
total 429.8 [374 – 484] 398.5 [352 – 446] 441.7 [382.4–502.1] 559.8 [481–637.4] 1002 [863.4–1139.5] 100
doi:10.1371/journal.pone.0026864.t004
Table 5. Indirect cost of T2DM by age and sex group [USD].
Total cost [million USD]
Cost category Subcategory
Average per capita
cost[USD] Male Female
Percent of total
indirect cost (both
sexes)
Temporarily Disability 20–39 24.3 28.8 3.1
40–59 97.1 115 12.2
60–69 32.2 38.2 4
Total (both sexes) 166.9 335.7 19.3
Permanently Disability 20–39 32.8 38.9 4.1
40–59 130.9 155.1 16.4
60–69 43.4 51.4 5.5
Total (both sexes) 225 452.4 26
Premature mortality 20–29 19 10.5 1.7
30–39 45.3 45.5 5.2
40–49 73.4 96.2 9.8
50–59 146.3 178.5 18.7
60–69 173.5 162.2 19.3
Total (both sexes) 472.7 950.3 54.7
Total indirect cost 864.8 1738.4 100
doi:10.1371/journal.pone.0026864.t005
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diagnosed and undiagnosed patients therefore multiplying per
capita cost by total number of diabetic patients (diagnosed and
undiagnosed) is not very accurate and suggested. Timothy and his
colleague found that annual per capita direct cost in patient with
diagnosed diabetes was 5.5 time higher than undiagnosed patient
(9677 and 1745 USD) [29,30]. Given that, about 30 to 50 percent
of total diabetic patients in Iran are undiagnosed [31,23], if people
with undiagnosed diabetes have diabetes-related medical costs that
are 10, 20, or 30% as high as people with diagnosed diabetes, then
the national cost of T2DM could be $136, $273 or $409 million
higher, respectively, than our estimates suggest.
Total estimated indirect cost of diabetes in Iran was 1.73 billion.
Lost productive time cost that was expressed as an average across
all individuals who met criteria for T2DM was 864.8 USD per
years. We found that indirect costs accounted for 44.5% of
diabetes-related total costs in Iran, whereas in recent studies in
USA and Colombia this proportion was 33% and 65.8%
respectively [10,32].
Our findings are robust to all of our base-case assumptions in
one-way sensitivity analyses. Some may argue that one way
sensitivity analysis could substantially underestimate the uncer-
tainty in cost of illness estimates [18]. To address this concern, the
effect of our simultaneous change of all unit costs by 620%
resulted in moderate changes in our estimates of direct health care
cost.
The findings in this study may be subject to several limitations
such as: absence of a single data source for all estimates, small
sample size in some data sources, correlation of both diabetes and
its co morbidities with other factors such as age and obesity. Also
we did not take into account expenditures for prevention programs
targeted to people with diabetes (e.g., disease management
programs), research activities (e.g., to develop new drugs), and
administration costs (e.g., to administer the national programs, to
process insurance claims) in cost estimates due to data limitations.
This study did not include undiagnosed diabetes and intangible
cost (reduced quality of life, and the pain and suffering of people
with diabetes, their families, and their friends) therefore, the health
care costs attributable to T2DM have been underestimated. The
lost productivity estimates are for those individuals with diagnosed
diabetes and exclude lost productivity associated with diabetes of
family members. For example, the productivity loss associated with
adults who take time off from work to care for an elderly parent is
not included in the cost estimates. Moreover, the extrapolation of
results from Tehran and Fars to Iran should be interpreted with
caution. Tehran and Shiraz seem to be more urbanized than other
provinces of country and accessing to health care facilities in these
provinces seems to be more than some other province and this
may cause overestimate the diabetes cost. In addition we used
human capital approach to estimate lost productive time cost but,
the hman capital approach may overestimate the costs, while the
frictional cost approach give more realistic estimates. The lack of
information needed to apply the frictional cost approach cause us
to apply first approach.
Many socioeconomic factors and healthcare system related
factors influence the outcome of diabetes and consequently its
costs. In this context, diabetes care in developing countries is
accompanied by certain societal issues patient behaviors, attitudes,
and beliefs, alongside issues such as finances and education, hinder
effective diabetes control [33]. As diabetes initially presents with
few symptoms and is not life-threatening, many people, particu-
larly in developing countries, often do not seek medical attention
until other incapacitating symptoms or complications develop
[34]. Delay in diagnosis can directly increase complications and
then lead to higher direct and indirect costs [25]. Awareness of
economic burden related to each complication of T2DM and what
drives cost can be very useful in health-system reform to
minimizing the long-term economic burden of this growing
epidemic.
Finally while diabetes mellitus is increasingly prevalent in the
Middle East, the population remains largely unaware of the
devastating effect of the disease. It is important both to educate
health professionals and the people in the region and to effectively
manage the disease in order to ultimately help control the
epidemic.
The present findings demonstrate that T2DM and its
complications impose significant burden on the individual and
health care system in Iran. Much of this cost is preventable
through improved diet and exercise and prevention initiatives to
reduce the prevalence of diabetes and its comorbidities. Improved
understanding of the economic cost of diabetes and the major
determinants of costs helps to inform and motivate decisions that
can reduce the national burden of this disease.
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